Magnetic Fluid Hyperthermia of Rodent Tumors Using Manganese Perovskite Nanoparticles

Purpose. To test the antitumor activity of magnetic fluid (MF) on the basis of substituted lanthanum-strontium manganite nanoparticles combined with alternating magnetic field (AMF) in experiments with transplanted tumors. Materials and Methods. MF with a size of nanoparticles of 30–40 nm in aqueous agarose solution was investigated. The ability of MF to heat tumor under AMF (300 kHz, 7.7 kA/m) was tested in vivo with rodent tumors (Guerin carcinoma, Walker-256 carcinosarcoma, and Lewis lung carcinoma (3LL)). Results. Single administration of MF into the tumor at a dose of 150 mg/kg (rats) or 200 mg/kg (mice) followed by AMF within 20–30 min (treatment was repeated 3-4-fold) has resulted in the complete regression of tumor in the 35% of rats and 57% of mice. Administration of MF alone or action of AMF alone has not resulted in tumor growth inhibition. The chemomodifying effect of nanohyperthermia was determined, in particular for cisplatinum: thermal enhancement ratio was 2.0. It was also observed that nanohyperthermia has resulted in the absence of 3LL metastases in 43% of mice. Conclusions. MF on the basis of lanthanum-strontium manganite may be considered as an effective inductor of tumor local hyperthermia.

Download Full-text

Silica-coated gadolinium-doped lanthanum strontium manganite nanoparticles for self-controlled hyperthermia applications

AIP Advances ◽

10.1063/1.5011717 ◽

2018 ◽

Vol 8 (1) ◽

pp. 015108 ◽

Cited By ~ 3

Author(s):

Ashfaq Ahmad ◽

Hongsub Bae ◽

Ilsu Rhee

Keyword(s):

Lanthanum Strontium Manganite ◽

Lanthanum Strontium ◽

Manganite Nanoparticles

Download Full-text

Evaluation of La1−xSrxMnO3 (0 ≤ x < 0.4) synthesised via a modified sol–gel method as mediators for magnetic fluid hyperthermia

CrystEngComm ◽

10.1039/c5ce01890k ◽

2016 ◽

Vol 18 (3) ◽

pp. 407-416 ◽

Cited By ~ 32

Author(s):

K. McBride ◽

J. Cook ◽

S. Gray ◽

S. Felton ◽

L. Stella ◽

...

Keyword(s):

Crystal Structure ◽

Magnetic Fluid ◽

Sol Gel ◽

Magnetic Fluid Hyperthermia ◽

Gel Method ◽

Sol Gel Method ◽

Lanthanum Strontium ◽

Sol Gel Synthesis

A range of lanthanum strontium manganates (La1−xSrxMnO3) where 0 ≤ x ≤ 0.4 were prepared using a modified peroxide sol–gel synthesis. The crystal structure of these materials was investigated and their potential as mediators for magnetic fluid hyperthermia was evaluated.

Download Full-text

Study on structural, magnetic and electrical properties of perovskite lanthanum strontium manganite nanoparticles

Journal of Materials Science Materials in Electronics ◽

10.1007/s10854-020-04608-9 ◽

2020 ◽

Vol 31 (23) ◽

pp. 20945-20953

Author(s):

G. Jayakumar ◽

D. S. Poomagal ◽

A. Albert Irudayaraj ◽

A. Dhayal Raj ◽

S. Kethrin Thresa ◽

...

Keyword(s):

Electrical Properties ◽

Lanthanum Strontium Manganite ◽

Lanthanum Strontium ◽

Manganite Nanoparticles ◽

Magnetic And Electrical Properties

Download Full-text

Manganite perovskite nanoparticles for self-controlled magnetic fluid hyperthermia: about the suitability of an aqueous combustion synthesis route

Journal of Materials Chemistry ◽

10.1039/c0jm03963b ◽

2011 ◽

Vol 21 (12) ◽

pp. 4393 ◽

Cited By ~ 69

Author(s):

Romain Epherre ◽

Etienne Duguet ◽

Stéphane Mornet ◽

Emil Pollert ◽

Stéphanie Louguet ◽

...

Keyword(s):

Combustion Synthesis ◽

Magnetic Fluid ◽

Magnetic Fluid Hyperthermia ◽

Synthesis Route ◽

Manganite Perovskite ◽

Perovskite Nanoparticles

Download Full-text

The Bcl-2 Family Inhibitor ABT-263 Shows Significant Anti-Tumor Efficacy in Models of B Cell Non-Hodgkin’s Lymphoma.

Blood ◽

10.1182/blood.v108.11.825.825 ◽

2006 ◽

Vol 108 (11) ◽

pp. 825-825

Author(s):

Alex R. Shoemaker ◽

Michael J. Mitten ◽

Anatol Oleksijew ◽

Jacqeuline M. O’Connor ◽

Baole Wang ◽

...

Keyword(s):

Tumor Growth ◽

Growth Inhibition ◽

B Cell ◽

Cell Lymphoma ◽

Cytotoxic Agents ◽

Tumor Growth Inhibition ◽

Complete Regression ◽

Mantle Cell

Abstract ABT-263 is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins with a Ki of ≤ 1 nM against Bcl-2, Bcl-XL, and Bcl-w. Non-Hodgkin’s B-cell lymphomas represent clinically relevant disease targets for this molecule due, in part, to strong expression of Bcl-2 often associated with various types of NHL (frequently involving a t(14;18) translocation including the Bcl-2 locus). ABT-263 exhibits sub-micromolar in vitro activity against a variety of NHL cell lines. DoHH-2 and WSU-DLCL2 are two B-cell NHL lines harboring the t(14;18) translocation that exhibit differential in vitro sensitivity to ABT-263. Granta-519 is a mantle cell lymphoma line with the characteristic t(11;14)(q13:q32) translocation resulting in overexpression of cyclin D1. ABT-263 has an EC50 of approximately 150 nM in the Granta-519 cell line. Here we present efficacy data evaluating the activity of ABT-263 in several NHL xenograft models. ABT-263 has significant in vivo anti-tumor efficacy in established flank tumor models both as monotherapy and in combination with cytotoxic agents. The efficacy of ABT-263 at 100 mg/kg/day, p.o., q.d. ×21 was evaluated as monotherapy and in combination with etoposide, vincristine, modified CHOP, R-CHOP, bortezomib, rapamycin, and rituximab. Results show that ABT-263 significantly inhibits tumor growth as a monotherapy (~50–60% tumor growth inhibition) and enhances the efficacy of these cytotoxic agents in combination therapy. Statistically significant enhancement of tumor growth inhibition was observed for each combination relative to monotherapy treatment. Efficacy was maintained even when therapy was initiated on larger (~500 mm3) tumors. Combinations of ABT-263 + rapamycin and ABT-263 + rituximab result in complete regression of a significant percentage of established B cell lymphoma tumors for a sustained period of time in vivo. The combination of ABT-263 + R-CHOP resulted in complete regression of 100% of the tumors in the mantle cell lymphoma model. The strong in vitro potency and tumor regressions seen in vivo suggest that ABT-263 has great potential for the oral treatment of NHL B-cell lymphomas.

Download Full-text

New insights into the heating mechanisms and self-regulating abilities of manganite perovskite nanoparticles suitable for magnetic fluid hyperthermia

Nanoscale ◽

10.1039/c2nr30667k ◽

2012 ◽

Vol 4 (13) ◽

pp. 3954 ◽

Cited By ~ 47

Author(s):

Eva Natividad ◽

Miguel Castro ◽

Graziella Goglio ◽

Irene Andreu ◽

Romain Epherre ◽

...

Keyword(s):

Magnetic Fluid ◽

Magnetic Fluid Hyperthermia ◽

Manganite Perovskite ◽

Perovskite Nanoparticles

Download Full-text

Micron-sized iron oxide particles for both MRI cell tracking and magnetic fluid hyperthermia treatment

Scientific Reports ◽

10.1038/s41598-021-82095-6 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Laurence Dallet ◽

Dimitri Stanicki ◽

Pierre Voisin ◽

Sylvain Miraux ◽

Emeline J. Ribot

Keyword(s):

Iron Oxide ◽

Magnetic Fluid ◽

Cell Tracking ◽

Significant Rise ◽

Iron Oxide Particles ◽

Hyperthermia Treatment ◽

Magnetic Fluid Hyperthermia ◽

Oxide Particles ◽

Endocytic Pathways

AbstractIron oxide particles (IOP) are commonly used for Cellular Magnetic Resonance Imaging (MRI) and in combination with several treatments, like Magnetic Fluid Hyperthermia (MFH), due to the rise in temperature they provoke under an Alternating Magnetic Field (AMF). Micrometric IOP have a high sensitivity of detection. Nevertheless, little is known about their internalization processes or their potential heat power. Two micrometric commercial IOP (from Bangs Laboratories and Chemicell) were characterized by Transmission Electron Microscopy (TEM) and their endocytic pathways into glioma cells were analyzed. Their Specific Absorption Rate (SAR) and cytotoxicity were evaluated using a commercial AMF inductor. T2-weighted imaging was used to monitor tumor growth in vivo after MFH treatment in mice. The two micron-sized IOP had similar structures and r2 relaxivities (100 mM−1 s−1) but involved different endocytic pathways. Only ScreenMAG particles generated a significant rise in temperature following AMF (SAR = 113 W g−1 Fe). After 1 h of AMF exposure, 60% of ScreenMAG-labeled cells died. Translated to a glioma model, 89% of mice responded to the treatment with smaller tumor volume 42 days post-implantation. Micrometric particles were investigated from their characterization to their intracellular internalization pathways and applied in one in vivo cancer treatment, i.e. MFH.

Download Full-text

Interplay between superparamagnetic and blocked behavior in an ensemble of lanthanum–strontium manganite nanoparticles

Physical Chemistry Chemical Physics ◽

10.1039/c7cp05547a ◽

2017 ◽

Vol 19 (39) ◽

pp. 27015-27024 ◽

Cited By ~ 10

Author(s):

V. M. Kalita ◽

D. M. Polishchuk ◽

D. G. Kovalchuk ◽

A. V. Bodnaruk ◽

S. O. Solopan ◽

...

Keyword(s):

Magnetic Nanoparticles ◽

Lanthanum Strontium Manganite ◽

Lanthanum Strontium ◽

Manganite Nanoparticles ◽

Health Related

Magnetic nanoparticles constitute promising tools for addressing medical and health-related issues based on the possibility to obtain various kinds of responses triggered by safe remote stimuli.

Download Full-text

The effect of copper nanoparticles on the progression of tumor in vivo.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.3084 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 3084-3084 ◽

Cited By ~ 1

Author(s):

Polina Sergeevna Kachesova ◽

Irina Aleksandrovna Goroshinskaya ◽

Vladimir Borisovich Borodulin

Keyword(s):

Tumor Growth ◽

Copper Nanoparticles ◽

Male Rats ◽

Control Group ◽

Entire Group ◽

Tumor Growth Inhibition ◽

Complete Regression ◽

Fusiform Cell ◽

Sarcoma 45

3084 Background: The study of the anticancer activity of copper nanoparticles (CuNP) measuring 70-75 nm in rats transplantable tumors. Methods: Experiments were carried out on white outbreed male rats with transplanted sarcoma 45 (9.10-dimethyl-1.2-benzanthracene-induced fusiform cell fibrosarcoma, S-45) and Pliss’s lymphosarcoma (Pliss). 0.5 ml of tumor tissue suspension (1x106 cells) in saline was inoculated subcutaneously in rat dorsal region for induction of sarcoma 45 or Pliss's lymphosarcoma. 7-8 days after tumors transplantation the animals were divided into three groups. Group 1: control (rats received 0.3 ml of saline only). Group 2: CuNP in 0.9% w/v of NaCl were injected intratumorally (1.25 mg/kg bodyweight). Group 3: The same amount of CuNP was injected intraperitonially. Animals received nanoparticles four times a week for one week, then after a week's break, the procedure was repeated. The associated nanoparticles are spherical in shape and have an oxide film on its surface. CuNP effect on tumor growth was determined by the mass (M) and size (V) of tumors. Results: The analysis of the received data showed that administration of CuNP to rats with S-45 caused reduced growth rates or cases with complete regression (8 of 17 cases) in 67.0% of experimental animals independently of injection way (V=0.81±0.3 cm3, M=0.91±0.3 g). The other 33% of rats with S-45 showed tumor growth (V=7.58±1.3 cm3, M=9.2±1.6 g). Overall, for the entire group of animals with S-45, nanoparticles inhibited tumor growth of 45%. In the control group there was an increase of tumor growth (V=9.0±1.8 cm3, M=10.4±2.5 g). CuNP introduction to animals with Pliss caused a delay in tumor growth and partial or complete regression (12 of 28 eight cases) in 40.0-48.0% of the rats in the route of Cu injection (V=1.4±0.8 cm3, M=10.4±2.5g). Observation of the remaining animals revealed tumor growth (V=60.6±5.93 cm3, M=67.13±8.7 g). In the whole group tumor growth inhibition was 50.0%. In the control group we observed increase of tumor growth (V=62.1±5.21 cm3, M=75.9±8.2 g). Conclusions: Thus the study showed that the copper nanoparticles possess antiproliferative activity, can inhibit the growth of transplanted tumors in rats and may be potentially used in anticancer medical therapy.

Download Full-text